Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Jan 09, 2021 7:39pm
169 Views
Post# 32262169

RE:Warrant extension implies 50-cents+ in two years

RE:Warrant extension implies 50-cents+ in two years

newdaydawning wrote: I believe that target is imminently doable if we accomplish just two things:

1. We get BTD for NMIBC supported by good outcomes from the US trials;

2  We get promising results from the early human trials showing TLD-1433's efficacy and safety for the treatment of - and protection against - Covid-19 and every other nasty virus.

Considering today's SP, a move to 50 cents minimum implies a return of 177% over 2 years!

IMO, the upside potential for TLT far outweighs the downside risk.

 

A one-two punch of a BTD plus promising Covid-19 results in early human trials should pique Pharma interest, moving us much higher than 50 cents imo.  

Not only do I believe in the science (I.e. no downside risk, just uncertain upside potential), I also believe that our trials should pick up steam as the North American grip on Covid finally tightens later this year with rising immunity (both naturally & via vaccination).  Also, as long as Canadian enrollment/treatment is able to remain steady, a BTD can be had before we see US data  (or even enrollment).  

In "two" years, if all goes as planned, we should be bought out in that time or at least a strong candidate for a buyout...& I will be bummed if we're still at $5.

<< Previous
Bullboard Posts
Next >>